Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
Left (3)
‘Landmark’: New mRNA vaccine could prevent skin cancer from returning, companies say
Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.
Aug 19, 2026
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Aug 19, 2026
Moderna, Merck Say mRNA Vaccine Prevents Melanoma From Returning
The companies say the vaccine prevented the return and spread of the cancer in high-risk melanoma patients.
Aug 19, 2026
Center (2)
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. The customized therapy, which could see a commercial launch next year, coul
Aug 19, 2026
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday. The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…
Aug 19, 2026